Pacira BioSciences (PCRX) Expected to Announce Quarterly Earnings on Thursday

Pacira BioSciences (NASDAQ:PCRX) is expected to announce its earnings results after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of $0.78 per share and revenue of $185.38 million for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Pacira BioSciences Stock Performance

Pacira BioSciences stock opened at $25.25 on Tuesday. The firm’s fifty day moving average price is $22.60 and its 200-day moving average price is $18.29. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The stock has a market cap of $1.17 billion, a P/E ratio of -12.44 and a beta of 0.80. Pacira BioSciences has a fifty-two week low of $11.16 and a fifty-two week high of $31.67.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on PCRX shares. Truist Financial upgraded shares of Pacira BioSciences from a “sell” rating to a “hold” rating and raised their price objective for the company from $8.00 to $25.00 in a research report on Thursday, January 30th. Needham & Company LLC boosted their price objective on shares of Pacira BioSciences from $22.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Royal Bank of Canada restated a “sector perform” rating and issued a $18.00 price objective on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Barclays decreased their price objective on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 12th. Finally, HC Wainwright restated a “buy” rating and issued a $39.00 price objective on shares of Pacira BioSciences in a research report on Wednesday, December 4th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $22.78.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.